Algernon Pharmaceuticals (AGN) AI Stock Analysis

• Market Cap: C$2.40M
• Dividend Yield: N/A
• Average Volume (3M): 29.71K
• Price to Earnings (P/E): 2.8
• Beta (1Y): -0.10
• Revenue Growth: N/A
• EPS Growth: 64.77%
• Country: CA
• Employees: 1
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 34,256,218
• 10 Day Avg. Volume: 15,726
• 30 Day Avg. Volume: 29,709
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: ―

Algernon Pharmaceuticals faces significant financial hurdles with zero revenue generation and ongoing operational losses, contributing to a low overall score. The technical indicators further suggest bearish momentum, while the valuation appears relatively attractive due to a low P/E ratio. However, the lack of earnings call and corporate events data limits further insight into potential future performance.

Algernon Pharmaceuticals Business Overview & Revenue Model

Company Description

Algernon Pharmaceuticals (AGN) is a clinical stage pharmaceutical development company focused on the discovery and development of novel therapeutic compounds for the treatment of non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD), acute and chronic cough, and fibrotic diseases. The company's innovative approach involves investigating and repurposing existing drugs to potentially expedite the development process and bring treatments to market more efficiently.

How the Company Makes Money

Algernon Pharmaceuticals makes money through the development and commercialization of its pharmaceutical products. The company focuses on repurposing existing drugs, which can streamline the approval process and reduce costs associated with drug development. Revenue is primarily generated through licensing agreements, partnerships with larger pharmaceutical companies, and potential sales of its proprietary compounds once approved. Additionally, Algernon may secure funding through grants or investment in its research and development initiatives. The company's earnings are influenced by the success of its clinical trials, regulatory approvals, and the ability to establish strategic partnerships for commercialization.

Algernon Pharmaceuticals Financial Statement Overview

Summary

Algernon Pharmaceuticals is facing significant financial challenges with zero revenue and operational losses. Although the balance sheet shows no debt and a reliance on equity, cash burn remains a persistent issue. The company needs to focus on generating revenue and improving operational efficiencies.

Income Statement

The company has consistently reported zero revenue, indicating a lack of commercialized products or services. Despite a reported positive net income in the TTM (Trailing-Twelve-Months), historical data shows significant net losses, demonstrating instability. The negative EBIT and EBITDA margins highlight ongoing operational challenges.

Balance Sheet

The company has a strong equity position with zero debt, reflected in a Debt-to-Equity Ratio of zero. However, the shrinking asset base and equity over the years suggest potential financial strain. The Equity Ratio shows moderate reliance on equity financing.

Cash Flow

Operating cash flows have been consistently negative, indicating operational cash challenges. Free cash flow has also been negative, pointing to cash outflows exceeding cash inflows. Financing activities have been necessary to support operations.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-26.56K	-50.40K	-34.94K	0.00	0.00
EBITDA	-476.42K	-4.98M	-6.02M	-8.05M	-8.54M
Net Income	-502.98K	-6.78M	-6.05M	-7.73M	-8.54M
Balance Sheet
Total Assets	3.94M	4.19M	8.14M	10.14M	12.82M
Cash, Cash Equivalents and Short-Term Investments	596.20K	125.08K	1.41M	2.41M	6.12M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.78M	2.72M	2.52M	1.02M	607.05K
Stockholders Equity	2.17M	1.47M	5.62M	9.12M	12.22M
Cash Flow
Free Cash Flow	-2.79M	-2.61M	-3.06M	-7.95M	-6.71M
Operating Cash Flow	-2.71M	-2.55M	-2.91M	-7.82M	-6.61M
Investing Cash Flow	2.28M	-59.50K	-144.61K	-124.45K	-99.74K
Financing Cash Flow	901.09K	1.33M	2.06M	4.25M	12.62M

Algernon Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.07
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AGN, the sentiment is Positive. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 57.62 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:AGN.

Algernon Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZOMD	77 Outperform	C$181.71M	7.81	85.19%	―	91.28%	623.60%
Sector *	47 Neutral	C$213.29M	-1.44	-30.58%	3.10%	19.48%	-0.04%
AGN	43 Neutral	C$2.40M	2.79	-93.09%	―	―	64.77%
ONC	43 Neutral	$143.94M	―	-244.84%	―	―	2.33%

Algernon Pharmaceuticals Corporate Events

Algernon NeuroScience Partners with Validcare for Pioneering Stroke Study

Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals, has appointed Validcare as the contract research organization for its upcoming Phase 2a DMT stroke trial in Europe. This trial will involve 40 stroke patients and is set to begin in the third quarter of 2025. Validcare, a U.S.-based CRO, has also invested $170,000 in Algernon NeuroScience, aligning incentives for efficient trial execution. The partnership aims to explore DMT’s potential in treating strokes by observing its effectiveness in reducing damage and restoring motor function. Additionally, Algernon Pharmaceuticals has announced the cancellation of 684,000 stock options previously granted to company officials.